Story perspectives

Veradermics Oral Minoxidil Hits Targets, Shares Surge 48%

4/28/2026

Summary

Story summary

Veradermics announced that its oral minoxidil pill VDPHL01 met trial endpoints, with the once-daily dose growing ~30 hairs/cm² in six months versus ~7 for placebo and the twice-daily dose adding ~33 hairs/cm².
79%–86% of treated participants reported improvement versus 36% on placebo, with adverse-event rates matched placebo, no serious cardiovascular events, and ~5% peripheral edema causing ~1% discontinuations.
Analysts projected $1.5-$2 billion U.S. sales, prompting shares to rise up to 48%.

1 of 1

Story summary

Veradermics announced that its oral minoxidil pill VDPHL01 met trial endpoints, with the once-daily dose growing ~30 hairs/cm² in six months versus ~7 for placebo and the twice-daily dose adding ~33 hairs/cm².
79%–86% of treated participants reported improvement versus 36% on placebo, with adverse-event rates matched placebo, no serious cardiovascular events, and ~5% peripheral edema causing ~1% discontinuations.
Analysts projected $1.5-$2 billion U.S. sales, prompting shares to rise up to 48%.